Cholestasis and cholestatic syndromes

Current Opinion in Gastroenterology

Volumn 23, Issue 3, 2007, Pages 232-236

  O'Leary, Jacqueline G ^a   Pratt, Daniel S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bile acid transport; Biliary atresia; Cholestasis; Intrahepatic cholestasis of pregnancy; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

BILE ACID; DEXAMETHASONE; MODAFINIL; PLACEBO; URSODEOXYCHOLIC ACID;

BILE ACID METABOLISM; BILE DUCT ATRESIA; CHOLESTASIS; CLINICAL TRIAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEREDITY; HUMAN; INTRAHEPATIC CHOLESTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PREGNANCY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REGULATORY MECHANISM; REVIEW; SOMNOLENCE; TREATMENT DURATION; TREATMENT PLANNING;

ANIMALS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLESTASIS; HUMANS; PROGNOSIS; SYNDROME; URSODEOXYCHOLIC ACID;

EID: 34147173947     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3280d942d8     Document Type: Review

References (28)

1. Stedman C, Liddle C, Coulter S, et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A 2006; 103:11323-11328. • FXR is known to be critical for bile acid regulation, but now may be a target for therapy of cholestatic liver diseases.
2. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130:1793-1806.
3. Paulusma CC, Groen A, Kunne C, et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 2006; 44:195-204.
4. Demeilliers C, Jacquemin E, Barbu V, et al. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR down-regulation. Hepatology 2006; 43:1125-1134.
5. Meier Y, Pauli-Magnus C, Zanger UM, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006; 44:62-74.
6. Hoofnagle JH, Sokol RJ. Neonatal screening for biliary atresia. Hepatology 2006; 43:646. • Neonatal screening for biliary atresia may be implemented.
7. Serinet MO, Broue P, Jacquemin E, et al. Management of patients with biliary atresia in France: results of a decentralized policy 1986-2002. Hepatology 2006; 44:75-84. • This well designed study shows that the prognosis of patients with biliary atresia is improving.
8. Shneider BL, Brown MB, Haber B, et al. A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr 2006; 148:467-474. • This study describes an important new way to predict prognosis of biliary atresia patients after Kasai.
9. Al-Masri AN, Flemming P, Rodeck B, et al. Expression of the interferon-induced Mx proteins in biliary atresia. J Pediatr Surg 2006; 41:1139-1143.
10. Shinkai M, Shinkai T, Puri P, Stringer MD. Increased CXCR3 expression associated with CD3-positive lymphocytes in the liver and biliary remnant in biliary atresia. J Pediatr Surg 2006; 41:950-954.
11. Beuers U, Pusl T. Intrahepatic cholestasis of pregnancy: a heterogeneous group of pregnancy-related disorders? Hepatology 2006; 43:647-649.
12. Floreani A, Carderi I, Paternoster D, et al. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther 2006; 23:1649-1653.
13. Ropponen A, Sund R, Riikonen S, et al. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology 2006; 43:723-728. •• A very interesting large population study of risk factors for ICP.
14. Vallejo M, Briz O, Serrano MA, et al. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol 2006; 44:1150-1157.
15. Reyes H, Zapata R, Hernandez I, et al. Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? Hepatology 2006;43:715-722.
16. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005; 42:1399-1405.
17. Lan RY, Cheng C, Lian ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006; 43:729-737.
18. Chuang YH, Lian ZX, Tsuneyama K, et al. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun 2006; 26:232-240.
19. Irie J, Wu Y, Wicker LS, et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006; 203:1209-1219. •• A novel mouse model of PBC that shows great promise for understanding the genetics and evaluating new treatments for PBC.
20. Inamura K, Tsuji H, Nakamoto Y, et al. Transgenic mice aberrantly expressing pyruvate dehydrogenase complex E2 component on biliary epithelial cells do not show primary biliary cirrhosis. Clin Exp Immunol 2006; 145:93-100.
21. Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101:1529-1538. •• PBC patients initiated on UDCA while they are stage 1 or 2 have an excellent prognosis.
22. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis: results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006;101:2044-2050. •• The prognosis of PBC patients with an abnormal bilirubin or albumin is accurately predicted by the Mayo model. The prognosis of PBC patients with a normal bilirubin and albumin, however, is excellent.
23. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130:715-720. •• A 40% reduction in alkaline phosphatase with UDCA at 1 year portends an excellent prognosis.
24. Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006; 20:211-220. • The outcome of liver transplantation in patients with PBC is excellent.
25. Newton JL, Gibson GJ, Tomlinson M, et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006; 44:91-98.
26. Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4:514-520.
27. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43:1118-1124. •• Transient elastrography is an exciting noninvasive technology that determines METAVIR stage fairly accurately.
28. Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130:465-481. • 24-nor-Ursodeoxycholic acid shows promise for the treatment of PSC.